Biopharmaceutical Fermentation Systems Market to Reach US$ 17.8 Bn by 2026
The global biopharmaceutical fermentation systems market was valued at around US$ 10.0 Bn in 2017 and is anticipated to expand at a CAGR of more than 6.0% from 2018 to 2026 to reach a value of around US$ 17.8 Bn in 2026. Emphasis on the development and marketing of innovative products and solutions such as single-use systems and continuous bioprocessing is likely to drive the biopharmaceutical fermentation systems market market. Moreover, expansion by key players in emerging markets through contracts and collaborations is anticipated to propel the market in the coming years. For instance, expansion in Asia Pacific through flexible and modular manufacturing facility solutions and collaboration with biopharmaceutical manufacturers to develop and improve bioprocess products.
In terms of application, the recombinant proteins segment held a major market share in 2017. High reliance on microbial systems for recombinant protein production contributed toward the leading share of the segment. Increase in investment in research activities and introduction of new protein therapeutics have significantly contributed to the development of recombinant therapeutic antibodies and proteins. Moreover, rise in the number of clinical trials in the pharmaceutical industry have boosted the segment in past few years. The recombinant proteins segment is expected to dominate the market during the forecast period, owing to an increased focus on developing innovative fusion protein and antibody-drug conjugates products.
Based on end-user, the biopharmaceutical companies segment accounted for a major market share in 2017. Well-equipped infrastructure and strong expertise have led to the dominant share of the segment. Biopharmaceutical companies such as Shire plc, AstraZeneca, Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Amgen have a wide portfolio of biological drugs. These companies are investing in the development of new biotherapeutics. With near-term patent expiry of blockbuster biologicals, biosimilars and biobetters are estimated to enter the market. This is expected to increase the adoption of microbial fermentation systems among biopharmaceutical companies. Furthermore, these key manufacturers are expanding their operations in emerging regions such as Asia Pacific and Latin America for better market access and regulatory compliance.
Perceive the Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=46989
In terms of region, the biopharmaceutical fermentation systems market is dominated by developed economic regions such as North America and Europe, owing to rapid development of biopharmaceuticals-derived techniques in these two regions. Additionally, significant research support in terms of infrastructure and funding has driven the biopharmaceutical fermentation systems market in the past decade. The market in emerging regions, such as Asia Pacific and the Rest of the World, is expected to expand at a rapid pace due to robust economic development and increase in demand for therapeutics in these regions Owing to reforms and economic growth, developing countries have been successful in attracting investment from prominent players. These regions allow market players to increase customer base and expand their business. Moreover, key players are introducing automation technologies and solutions to integrate microbial fermentation systems in order to analyze and monitor culture process and increase efficacy of the production process. For instance, GE Healthcare has collaborated with Zenith Technologies and Emerson Process Management to offer automation solutions through its FlexFactory and KUBio biopharmaceutical manufacturing facilities. These technological advances in microbial fermentation systems are likely to fuel the adoption of microbial cell systems for the production of biopharmaceuticals in the near future.
Prominent players operating in the global biopharmaceutical fermentation systems market include GE Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius StedimBiotech, Merck KGaA, Eppendorf AG, F. Hoffmann-La Roche Ltd., Nova Biomedicals, Lonza, and Becton, and Dickinson and Company. Sartorius Stedim Biotech has been offering innovative solutions for microbial fermentation such as large-scale single-use microbial fermenters, process monitoring systems, and filtration and chromatography systems over the years. The company is a leading supplier of microbial fermentation systems. Another major player is Merck KGaA, which has a wide portfolio of bioprocess products and solutions. Merck has expertise in downstream products with single-use and reusable filtration and chromatography systems and consumables. There are numerous small- and medium-scale suppliers of bioprocess and other fermentation products, which has led to a fragmented market. However, among biopharmaceutical companies and CDMOs, the top five players are major suppliers of microbial bioprocess solutions and products. They account for 45% to 50% of the revenue generated from these end-users.
Obtain the Brochure of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46989
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453